BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cells » HSCs » Page 3

Hematopoietic Stem Cells (HSCs)

When Did Cord Blood Banking Start? Landmark Events in Cord Blood & Tissue

By

The global cord blood industry came into existence in the early 1990’s with the formation of several leading cord blood banks in the USA, followed by the establishment of cord blood banks across the globe. However, the history of cord blood stem cell transplantation begins much earlier than that.

The History of Banking Cord Blood

In this article:

[Read more…]

Could NiCord® by Gamida Cell Introduce a Paradigm Shift to HSCT?

By

Gamida CellGamida Cell is an Israeli company specializing in cellular and immune therapies for the treatment of cancer and orphan genetic diseases. The company is developing a diverse clinical pipeline based on its proprietary NAM technology platform. It lead program, NiCord®, is now in Phase 3 development for allogeneic bone marrow transplantation.

NiCord® was granted Breakthrough Therapy Designation by the FDA, as well orphan drug designation by the European Medicines Agency (EMA). [Read more…]

Cord Blood Industry Trends – Clinical Trials, Publications, Patents, Grants, & More

By

With the global cord blood banking industry maturing and consolidating over the past five years, it is more important than ever to be well-educated about cord blood industry trends. There are now fewer market players, because numerous small cord blood banks have either been acquired or gone out of business.

However, this era of maturation and consolidation has had as many benefits to surviving cord blood banks as drawbacks. On average, the remaining market participants are now larger, stronger, better capitalized, and storing larger quantities of cord blood and tissue units than when the market was more fragmented.

[Read more…]

Cord Blood Processing Method PrepaCyte-CB Leads in Engraftment Time

By

The cord blood processing method PrepaCyte-CB has been shown to engraft more quickly during the vital stage of post-transplant recovery than any other processing method. At the 15th Annual International Cord Blood Symposium in San Diego, California, in June 2017, the St. Louis Cord Blood Bank presented the median time it took patients infused with cord blood using either its Hetastarch  or PrepaCyte-CB processing method to reach an absolute neutrophil count (ANC) of 500.

PrepaCyte-CB was found to engraft a full four days more quickly than the Hetastarch processing method (16 days versus 20 days) and has shown to be just as safe to the patient.1 Combining this data with those of other public data sources, PrepaCyte-CB was found to engraft more quickly than any other processing method. [Read more…]

BioInformant's World-Class Clients